Adaptive immunity and atherosclerosis

Clinical Immunology

Volumn 134, Issue 1, 2010, Pages 33-46

  Andersson, John ^a   Libby, Peter ^b   Hansson, Göran K ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anti inflammatory cytokines; Atherosclerosis; Coinhibition; Costimulation; Pro inflammatory cytokines; Regulatory T cells; Statins; T cells; Th1; Th2

Indexed keywords

B7 ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CYCLOSPORIN A; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; OX40 LIGAND; T LYMPHOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; COMPREHENSION; HUMAN; INTERVENTION STUDY; MODULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; MODELS, BIOLOGICAL; T-LYMPHOCYTES;

EID: 71649108018     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.07.002     Document Type: Review

References (161)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
2. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6 (2006) 508-519
3. Weber C., Zernecke A., and Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol. 8 (2008) 802-815
4. Jonasson L., Holm J., Skalli O., Gabbiani G., and Hansson G.K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76 (1985) 125-131
5. Hansson G.K., Jonasson L., Holm J., and Claesson-Welsh L. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin. Exp. Immunol. 64 (1986) 261-268
6. Hansson G.K., Holm J., and Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135 (1989) 169-175
7. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., and Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 1372-1376
8. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., and Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3893-3897
9. Cybulsky M.I., and Gimbrone Jr. M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251 (1991) 788-791
10. Nakashima Y., Raines E.W., Plump A.S., Breslow J.L., and Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 842-851
11. Dai G., Kaazempur-Mofrad M.R., Natarajan S., Zhang Y., Vaughn S., Blackman B.R., Kamm R.D., Garcia-Cardena G., and Gimbrone Jr. M.A. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14871-14876
12. Skalen K., Gustafsson M., Rydberg E.K., Hulten L.M., Wiklund O., Innerarity T.L., and Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417 (2002) 750-754
13. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., Bergmeier W., Richter T., Lorenz M., Konrad I., Nieswandt B., and Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196 (2002) 887-896
14. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
15. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., and Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2 (1998) 275-281
16. Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J., and Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8264-8268
17. Edfeldt K., Swedenborg J., Hansson G.K., and Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105 (2002) 1158-1161
18. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J. Intern. Med. 263 (2008) 517-527
19. Breslow J.L. Mouse models of atherosclerosis. Science 272 (1996) 685-688
20. Roselaar S.E., Kakkanathu P.X., and Daugherty A. Lymphocyte populations in atherosclerotic lesions of apoE-/- and LDL receptor-/- mice. Decreasing density with disease progression. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1013-1018
21. Emeson E.E., Shen M.L., Bell C.G., and Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am. J. Pathol. 149 (1996) 675-685
22. Huber S.A., Sakkinen P., David C., Newell M.K., and Tracy R.P. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 103 (2001) 2610-2616
23. Song L., Leung C., and Schindler C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108 (2001) 251-259
24. Daugherty A., Pure E., Delfel-Butteiger D., Chen S., Leferovich J., Roselaar S.E., and Rader D.J. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J. Clin. Invest. 100 (1997) 1575-1580
25. Dansky H.M., Charlton S.A., Harper M.M., and Smith J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4642-4646
26. Reardon C.A., Blachowicz L., White T., Cabana V., Wang Y., Lukens J., Bluestone J., and Getz G.S. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1011-1016
27. Zhou X., Nicoletti A., Elhage R., and Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102 (2000) 2919-2922
28. Zhou X., Robertson A.K., Rudling M., Parini P., and Hansson G.K. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ. Res. 96 (2005) 427-434
29. Elhage R., Gourdy P., Brouchet L., Jawien J., Fouque M.J., Fievet C., Huc X., Barreira Y., Couloumiers J.C., Arnal J.F., and Bayard F. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am. J. Pathol. 165 (2004) 2013-2018
30. Ludewig B., Freigang S., Jaggi M., Kurrer M.O., Pei Y.C., Vlk L., Odermatt B., Zinkernagel R.M., and Hengartner H. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12752-12757
31. Olofsson P.S., Soderstrom L.A., Wagsater D., Sheikine Y., Ocaya P., Lang F., Rabu C., Chen L., Rudling M., Aukrust P., Hedin U., Paulsson-Berne G., Sirsjo A., and Hansson G.K. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117 (2008) 1292-1301
32. Bobryshev Y.V. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur. Heart J. 26 (2005) 1700-1704
33. Bobryshev Y.V., and Lord R.S. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc. Res. 37 (1998) 799-810
34. Murray A.G., Libby P., and Pober J.S. Human vascular smooth muscle cells poorly co-stimulate and actively inhibit allogeneic CD4+ T cell proliferation in vitro. J. Immunol. 154 (1995) 151-161
35. De Palma R., Del Galdo F., Abbate G., Chiariello M., Calabro R., Forte L., Cimmino G., Papa M.F., Russo M.G., Ambrosio G., Giombolini C., Tritto I., Notaristefano S., Berrino L., Rossi F., and Golino P. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 113 (2006) 640-646
36. Paulsson G., Zhou X., Tornquist E., and Hansson G.K. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 10-17
37. Liuzzo G., Goronzy J.J., Yang H., Kopecky S.L., Holmes D.R., Frye R.L., and Weyand C.M. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101 (2000) 2883-2888
38. Palinski W., and Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J. Intern. Med. 247 (2000) 371-380
39. Epstein S.E., Zhou Y.F., and Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 100 (1999) e20-e28
40. Mayr M., Kiechl S., Willeit J., Wick G., and Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and Cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 102 (2000) 833-839
41. Kalayoglu M.V., Libby P., and Byrne G.I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288 (2002) 2724-2731
42. Kleindienst R., Xu Q., Willeit J., Waldenberger F.R., Weimann S., and Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am. J. Pathol. 142 (1993) 1927-1937
43. George J., Shoenfeld Y., Afek A., Gilburd B., Keren P., Shaish A., Kopolovic J., Wick G., and Harats D. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 505-510
44. Xu Q., Dietrich H., Steiner H.J., Gown A.M., Schoel B., Mikuz G., Kaufmann S.H., and Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12 (1992) 789-799
45. Xu Q., Kiechl S., Mayr M., Metzler B., Egger G., Oberhollenzer F., Willeit J., and Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 100 (1999) 1169-1174
46. Xu Q., Willeit J., Marosi M., Kleindienst R., Oberhollenzer F., Kiechl S., Stulnig T., Luef G., and Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341 (1993) 255-259
47. Palinski W., Tangirala R.K., Miller E., Young S.G., and Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1569-1576
48. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., and Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
49. Zhou X., Robertson A.K., Hjerpe C., and Hansson G.K. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 864-870
50. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., Barshack I., Kopolovic J., and Shoenfeld Y. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99 (1999) 2227-2230
51. Wu R., Nityanand S., Berglund L., Lithell H., Holm G., and Lefvert A.K. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3159-3163
52. George J., Afek A., Gilburd B., Blank M., Levy Y., Aron-Maor A., Levkovitz H., Shaish A., Goldberg I., Kopolovic J., Harats D., and Shoenfeld Y. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98 (1998) 1108-1115
53. Tupin E., Nicoletti A., Elhage R., Rudling M., Ljunggren H.G., Hansson G.K., and Berne G.P. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199 (2004) 417-422
54. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136 (1986) 2348-2357
55. Whitman S.C., Ravisankar P., and Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J. Interferon. Cytokine. Res. 22 (2002) 661-670
56. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., and Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99 (1997) 2752-2761
57. Buono C., Come C.E., Stavrakis G., Maguire G.F., Connelly P.W., and Lichtman A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 454-460
58. Whitman S.C., Ravisankar P., Elam H., and Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am. J. Pathol. 157 (2000) 1819-1824
59. Niwa T., Wada H., Ohashi H., Iwamoto N., Ohta H., Kirii H., Fujii H., Saito K., and Seishima M. Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J. Atheroscler. Thromb. 11 (2004) 79-87
60. Tellides G., Tereb D.A., Kirkiles-Smith N.C., Kim R.W., Wilson J.H., Schechner J.S., Lorber M.I., and Pober J.S. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 403 (2000) 207-211
61. Gerdes N., Sukhova G.K., Libby P., Reynolds R.S., Young J.L., and Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 195 (2002) 245-257
62. Melian A., Geng Y.J., Sukhova G.K., Libby P., and Porcelli S.A. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155 (1999) 775-786
63. Chan W.L., Pejnovic N., Liew T.V., Lee C.A., Groves R., and Hamilton H. NKT cell subsets in infection and inflammation. Immunol. Lett. 85 (2003) 159-163
64. Leon M.L., and Zuckerman S.H. Gamma interferon: a central mediator in atherosclerosis. Inflamm. Res. 54 (2005) 395-411
65. Harvey E.J., and Ramji D.P. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?. Cardiovasc. Res. 67 (2005) 11-20
66. Hansson G.K., Hellstrand M., Rymo L., Rubbia L., and Gabbiani G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170 (1989) 1595-1608
67. Amento E.P., Ehsani N., Palmer H., and Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11 (1991) 1223-1230
68. McLaren J.E., and Ramji D.P. Interferon gamma: a master regulator of atherosclerosis. Cytokine. Growth Factor Rev. 20 (2009) 125-135
69. Buono C., Binder C.J., Stavrakis G., Witztum J.L., Glimcher L.H., and Lichtman A.H. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1596-1601
70. Lord G.M., Rao R.M., Choe H., Sullivan B.M., Lichtman A.H., Luscinskas F.W., and Glimcher L.H. T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood 106 (2005) 3432-3439
71. Schulte S., Sukhova G.K., and Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am. J. Pathol. 172 (2008) 1500-1508
72. Davenport P., and Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163 (2003) 1117-1125
73. King V.L., Szilvassy S.J., and Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 456-461
74. Leskinen M.J., Kovanen P.T., and Lindstedt K.A. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells-a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem. Pharmacol. 66 (2003) 1493-1498
75. Shimizu K., Shichiri M., Libby P., Lee R.T., and Mitchell R.N. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J. Clin. Invest. 114 (2004) 300-308
76. Binder C.J., Hartvigsen K., Chang M.K., Miller M., Broide D., Palinski W., Curtiss L.K., Corr M., and Witztum J.L. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114 (2004) 427-437
77. Horkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., and Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103 (1999) 117-128
78. Shevach E.M., DiPaolo R.A., Andersson J., Zhao D.M., Stephens G.L., and Thornton A.M. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212 (2006) 60-73
79. Veillard N.R., Steffens S., Burger F., Pelli G., and Mach F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2339-2344
80. Heller E.A., Liu E., Tager A.M., Yuan Q., Lin A.Y., Ahluwalia N., Jones K., Koehn S.L., Lok V.M., Aikawa E., Moore K.J., Luster A.D., and Gerszten R.E. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113 (2006) 2301-2312
81. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., Merval R., Esposito B., Cohen J.L., Fisson S., Flavell R.A., Hansson G.K., Klatzmann D., Tedgui A., and Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12 (2006) 178-180
82. Fahlen L., Read S., Gorelik L., Hurst S.D., Coffman R.L., Flavell R.A., and Powrie F. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 201 (2005) 737-746
83. Liesz A., Suri-Payer E., Veltkamp C., Doerr H., Sommer C., Rivest S., Giese T., and Veltkamp R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med. 15 (2009) 192-199
84. Mallat Z., Gojova A., Brun V., Esposito B., Fournier N., Cottrez F., Tedgui A., and Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 108 (2003) 1232-1237
85. Dardalhon V., Awasthi A., Kwon H., Galileos G., Gao W., Sobel R.A., Mitsdoerffer M., Strom T.B., Elyaman W., Ho I.C., Khoury S., Oukka M., and Kuchroo V.K. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9 (2008) 1347-1355
86. Veldhoen M., Uyttenhove C., van Snick J., Helmby H., Westendorf A., Buer J., Martin B., Wilhelm C., and Stockinger B. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9 (2008) 1341-1346
87. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., and Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6 (2005) 1133-1141
88. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., and Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005) 1123-1132
89. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
90. Eid R.E., Rao D.A., Zhou J., Lo S.F., Ranjbaran H., Gallo A., Sokol S.I., Pfau S., Pober J.S., and Tellides G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119 (2009) 1424-1432
91. Pejnovic N., Vratimos A., Lee S.H., Popadic D., Takeda K., Akira S., and Chan W.L. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol. Immunol. 47 (2009) 37-45
92. Song L., and Schindler C. IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 177 (2004) 43-51
93. Schaerli P., Willimann K., Lang A.B., Lipp M., Loetscher P., and Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192 (2000) 1553-1562
94. Breitfeld D., Ohl L., Kremmer E., Ellwart J., Sallusto F., Lipp M., and Forster R. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192 (2000) 1545-1552
95. Gotsman I., Sharpe A.H., and Lichtman A.H. T-cell costimulation and coinhibition in atherosclerosis. Circ. Res. 103 (2008) 1220-1231
96. Buono C., and Lichtman A.H. Co-stimulation and plaque-antigen-specific T-cell responses in atherosclerosis. Trends. Cardiovasc. Med. 14 (2004) 166-172
97. de Boer O.J., Hirsch F., van der Wal A.C., van der Loos C.M., Das P.K., and Becker A.E. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis 133 (1997) 227-234
98. Vallejo A.N., Weyand C.M., and Goronzy J.J. T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol. Med. 10 (2004) 119-124
99. Pawlik A., Ostanek L., Brzosko I., Brzosko M., Masiuk M., Machalinski B., and Gawronska-Szklarz B. The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis. Res. Ther. 5 (2003) R210-R213
100. Pryshchep S., Sato K., Goronzy J.J., and Weyand C.M. T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circ. Res. 98 (2006) 1168-1176
101. Schonbeck U., Sukhova G.K., Shimizu K., Mach F., and Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7458-7463
102. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
103. Lutgens E., Cleutjens K.B., Heeneman S., Koteliansky V.E., Burkly L.C., and Daemen M.J. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7464-7469
104. Lutgens E., Gorelik L., Daemen M.J., de Muinck E.D., Grewal I.S., Koteliansky V.E., and Flavell R.A. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5 (1999) 1313-1316
105. Smook M.L., Heeringa P., Damoiseaux J.G., Daemen M.J., de Winther M.P., Gijbels M.J., Beckers L., Lutgens E., and Tervaert J.W. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 183 (2005) 275-282
106. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., and Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4342-4346
107. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ. Res. 89 (2001) 1092-1103
108. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res. 92 (2003) 1041-1048
109. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., and Kroczek R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
110. Olofsson P.S., Soderstrom L.A., Jern C., Sirsjo A., Ria M., Sundler E., de Faire U., Wiklund P.G., Ohrvik J., Hedin U., Paulsson-Berne G., Hamsten A., Eriksson P., and Hansson G.K. Genetic variants of TNFSF4 and risk for carotid artery disease and stroke. J. Mol. Med. 87 (2008) 337-346
111. Wang X., Ria M., Kelmenson P.M., Eriksson P., Higgins D.C., Samnegard A., Petros C., Rollins J., Bennet A.M., Wiman B., de Faire U., Wennberg C., Olsson P.G., Ishii N., Sugamura K., Hamsten A., Forsman-Semb K., Lagercrantz J., and Paigen B. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 37 (2005) 365-372
112. van Wanrooij E.J., van Puijvelde G.H., de Vos P., Yagita H., van Berkel T.J., and Kuiper J. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 204-210
113. Gotsman I., Grabie N., Gupta R., Dacosta R., MacConmara M., Lederer J., Sukhova G., Witztum J.L., Sharpe A.H., and Lichtman A.H. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114 (2006) 2047-2055
114. Herman A.E., Freeman G.J., Mathis D., and Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199 (2004) 1479-1489
115. Kohyama M., Sugahara D., Sugiyama S., Yagita H., Okumura K., and Hozumi N. Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4192-4197
116. Gotsman I., Grabie N., Dacosta R., Sukhova G., Sharpe A., and Lichtman A.H. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J. Clin. Invest. 117 (2007) 2974-2982
117. Uyemura K., Demer L.L., Castle S.C., Jullien D., Berliner J.A., Gately M.K., Warrier R.R., Pham N., Fogelman A.M., and Modlin R.L. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97 (1996) 2130-2138
118. Lee T.S., Yen H.C., Pan C.C., and Chau L.Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 734-742
119. Mallat Z., Corbaz A., Scoazec A., Besnard S., Leseche G., Chvatchko Y., and Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104 (2001) 1598-1603
120. Elhage R., Jawien J., Rudling M., Ljunggren H.G., Takeda K., Akira S., Bayard F., and Hansson G.K. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59 (2003) 234-240
121. Mallat Z., Corbaz A., Scoazec A., Graber P., Alouani S., Esposito B., Humbert Y., Chvatchko Y., and Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89 (2001) E41-E45
122. Whitman S.C., Ravisankar P., and Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res. 90 (2002) E34-E38
123. Tenger C., Sundborger A., Jawien J., and Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 791-796
124. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., and Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2137-2142
125. Avouac J., and Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert. Opin. Pharmacother. 9 (2008) 1121-1128
126. Grainger D.J., Kemp P.R., Metcalfe J.C., Liu A.C., Lawn R.M., Williams N.R., Grace A.A., Schofield P.M., and Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat. Med. 1 (1995) 74-79
127. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., Fradelizi D., and Tedgui A. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89 (2001) 930-934
128. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E., and Daemen M.J. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 975-982
129. Robertson A.K., Rudling M., Zhou X., Gorelik L., Flavell R.A., and Hansson G.K. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112 (2003) 1342-1350
130. Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., Soubrier F., Esposito B., Duez H., Fievet C., Staels B., Duverger N., Scherman D., and Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85 (1999) e17-e24
131. Pinderski Oslund L.J., Hedrick C.C., Olvera T., Hagenbaugh A., Territo M., Berliner J.A., and Fyfe A.I. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2847-2853
132. Pinderski L.J., Fischbein M.P., Subbanagounder G., Fishbein M.C., Kubo N., Cheroutre H., Curtiss L.K., Berliner J.A., and Boisvert W.A. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90 (2002) 1064-1071
133. Caligiuri G., Rudling M., Ollivier V., Jacob M.P., Michel J.B., Hansson G.K., and Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 9 (2003) 10-17
134. Potteaux S., Esposito B., van Oostrom O., Brun V., Ardouin P., Groux H., Tedgui A., and Mallat Z. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1474-1478
135. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
136. Zernecke A., Shagdarsuren E., and Weber C. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1897-1908
137. Veillard N.R., Steffens S., Pelli G., Lu B., Kwak B.R., Gerard C., Charo I.F., and Mach F. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 112 (2005) 870-878
138. Spring H., Schuler T., Arnold B., Hammerling G.J., and Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18111-18116
139. Quinones M.P., Martinez H.G., Jimenez F., Estrada C.A., Dudley M., Willmon O., Kulkarni H., Reddick R.L., Fernandes G., Kuziel W.A., Ahuja S.K., and Ahuja S.S. CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195 (2007) e92-e103
140. Ludwig A., and Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb. Haemost. 97 (2007) 694-703
141. Huttenlocher A., and Poznansky M.C. Reverse leukocyte migration can be attractive or repulsive. Trends Cell Biol. 18 (2008) 298-306
142. Emeson E.E., and Shen M.L. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am. J. Pathol. 142 (1993) 1906-1915
143. Roselaar S.E., Schonfeld G., and Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J. Clin. Invest. 96 (1995) 1389-1394
144. Drew A.F., and Tipping P.G. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 116 (1995) 181-189
145. Romero F., Rodriguez-Iturbe B., Pons H., Parra G., Quiroz Y., Rincon J., and Gonzalez L. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 152 (2000) 127-133
146. Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am. J. Transplant. 2 (2002) 807-818
147. Jonasson L., Holm J., and Hansson G.K. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2303-2306
148. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
149. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
150. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
151. Sena A., Pedrosa R., and Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol. 250 (2003) 754-755
152. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
153. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
154. Yilmaz A., Reiss C., Tantawi O., Weng A., Stumpf C., Raaz D., Ludwig J., Berger T., Steinkasserer A., Daniel W.G., and Garlichs C.D. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172 (2004) 85-93
155. Waiczies S., Prozorovski T., Infante-Duarte C., Hahner A., Aktas O., Ullrich O., and Zipp F. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J. Immunol. 174 (2005) 5630-5635
156. Gegg M.E., Harry R., Hankey D., Zambarakji H., Pryce G., Baker D., Adamson P., Calder V., and Greenwood J. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J. Immunol. 174 (2005) 2327-2335
157. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., Campbell C., Gracie J.A., Liew F.Y., and McInnes I.B. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170 (2003) 1524-1530
158. Greenwood J., Walters C.E., Pryce G., Kanuga N., Beraud E., Baker D., and Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17 (2003) 905-907
159. Weber C., Erl W., Weber K.S., and Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30 (1997) 1212-1217
160. Massy Z.A., Keane W.F., and Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet 347 (1996) 102-103
161. Mausner-Fainberg K., Luboshits G., Mor A., Maysel-Auslender S., Rubinstein A., Keren G., and George J. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197 (2008) 829-839